Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation
- PMID: 37093345
- PMCID: PMC11798138
- DOI: 10.1007/s00432-023-04781-4
Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation
Abstract
Purpose: Lymphoma-associated haemophagocytic syndrome (LAHS) is a group of malignant diseases with rapid progression and a high mortality rate. Our study aimed to discover the significance of serum sCD25/ferritin ratio as well as cytokines in assisting the diagnosis of LAHS.
Methods: We retrospectively analyzed the clinical data of 82 patients with LAHS with hemophagocytic lymphohistiocytosis (HLH) as the first manifestation and divided them into B-LAHS group and T/NK-LAHS group according to lymphoma pathological diagnosis for comparison. And patients with LAHS were divided into responding group, non-responding group according to the assessment of efficacy after receiving DEP/L-DEP induction therapy for 2 weeks to compare possible valuable indicators.
Results: Serum sCD25/ferritin ratio and MCP-1 levels were significantly different between B-LAHS and T/NK-LAHS groups (P = 0.001, P = 0.022). An sCD25/ferritin ratio > 7.8 tended to suggest a diagnosis of B-LAHS (AUC = 0.71, 95% CI: 0.596-0.823), and the sCD25/ferritin ratio had better predictive value when combined with MCP-1 (AUC = 0.81, 95% CI: 0.699-0.922). The sCD25/ferritin ratio was also significantly different between the two groups responding or not responding to induction therapy (P = 0.002), yielding an optimal cutoff value of 11.48. An sCD25/ferritin ratio > 11.48 tended to suggest that the patient's LAHS was responsive to induction therapy.
Conclusion: Our study reveals that serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation and may assist in predicting whether the lymphoma is of B-cell or T/NK-cell origin. The sCD25/ferritin ratio can also be used to predict the early response of LAHS after induction therapy.
Keywords: Cytokine; Diagnosis; Ferritin; Hemophagocytic lymphohistiocytosis; Non-Hodgkin lymphoma; sCD25.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The authors have no relevant financial or non-financial interests to disclose.
Figures
References
-
- Al-Samkari H, Berliner N (2018) Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 13:27–49. 10.1146/annurev-pathol-020117-043625 - PubMed
-
- Bains A, Mamone L, Aneja A, Bromberg M (2017) Lymphoid malignancy-associated hemophagocytic lymphohistiocytosis: search for the hidden source. Ann Diagn Pathol 28:37–42. 10.1016/j.anndiagpath.2017.02.009 - PubMed
-
- Chinese Physicians Association, Haematology Section, Chinese Medical Association, Haematology Group, Chinese Expert Alliance for Hemophagocytic Syndrome (2022) Chinese guidelines for the diagnosis and treatment of hemophagocytic syndrome (2022 edition). Chin Med J 102(20):1492–1499. 10.3760/cma.j.cn112137-20220310-00488
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
